I, DR PM MAHLATI, Acting Director General, have determined in accordance with Regulation 21 of the Regulations Relating to a Transparent Pricing System for Medicines and Scheduled Substances published in Government Gazette number 28214 of 11 November 2005, that the information required in the submissions for the 2023 Single Exit Price (SEP) adjustment as determined by the Minister be submitted to the Directorate: Pharmaceutical Economic Evaluation (PEE) within the National Department of Health by a manufacturer or importer of the medicine or scheduled substance, who is the applicant of the medicine, in accordance to the information and instruction document appended to this Notice.

Such information should be submitted electronically to [email protected]. The submission should include information containing the applicant's entire portfolio; including the medicines for which the applicant is not requesting an adjustment of the SEP.

Dr PM Mahlati

Acting Director-General: Health

Date:22/12/2022

Preamble

1. Acronyms

2. Applicant Information

3. How to complete template columns

4. Annexures